Stockreport

Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact ...

IceCure Medical Ltd. - Ordinary Shares  (ICCM) 
PDF More data is expected in the fourth quarter of 2024, including data on patients with an average follow up of approximately 3 years $6.92 billion global kidney cancer [Read more]